Skip to content
★ Sign in to follow
DN

David Norwood

Chairman
4D Pharma plc
Total declarations
6
Company
1
▲ Purchases (6 ops.)
€113k
▼ Sales (0 ops.)
—

Latest filing published 18 Mar 2020 for 4D Pharma plc, €31k.

Filing timeline

BuySale
David Norwood

Insider track record

Disclosed buys
6
Disclosed sells
0
Signal history

Closed purchases

Market purchases
6

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

David Norwood: trading record in brief

This profile gathers the share dealings of David Norwood in 4D Pharma plc. Over a trading history stretching from 19 December 2018 to 18 March 2020, the count stands at 6 filings.

Purchases make up the whole of the open-market record (6 purchases, €113k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Since January 2020: 1 purchase and no sales on the market.

The median purchase comes to €20k. On 3 out of 6 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 18 March 2020, the filings show an open-market purchase worth €31k in 4D Pharma plc. Publication is fast: at least half of the trades appear on RNS (LSE) on the same day. For comparison, UK MAR gives managers three business days to notify a trade. These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.

Companies and markets linked to David Norwood

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations6 total
  • ▲
    Chairman/ PDMRExecutives4D Pharma plc
    28,000 GBP15FCA-NSM
    100,000 shares@ £0.28100.0% of flowLondon Stock Exchange, AIMISIN GB00BJL5BR07FCA-NSM:LSE20200318074912_3531206_20200402164404231
    Canonical exit: 16 Jun 2020 (T+90)
  • ▲
    PDMRExecutives4D Pharma plc
    15,000 GBP25FCA-NSM
    15,000 shares@ £1.0018.9% of flowLondon Stock Exchange, AIMISIN GB00BJL5BR07FCA-NSM:LSE20190530070008_14091626_20200326185141071_3017
    Canonical exit: 28 Aug 2019 (T+90)
  • ▲
    PDMRExecutives4D Pharma plc
    4,800 GBP24FCA-NSM
    5,000 shares@ £0.966.1% of flowLondon Stock Exchange, AIMISIN GB00BJL5BR07FCA-NSM:LSE20190522070006_14082715_20200326185142053_11038-0
    Canonical exit: 20 Aug 2019 (T+90)
  • ▲
    PDMRExecutives4D Pharma plc
    19,540 GBP25FCA-NSM
    23,725 shares@ £0.823620.1% of flowLondon Stock Exchange, AIMISIN GB00BJL5BR07FCA-NSM:LSE20190313090801_14000449_20200326185134023_18179-0
    Canonical exit: 11 Jun 2019 (T+90)
  • ▲
    PDMRExecutives4D Pharma plc
    10,300 GBP12FCA-NSM
    10,000 shares@ £1.0312.7% of flowLondon Stock Exchange, AIMISIN GB00BJL5BR07FCA-NSM:LSE20181221070003_13912391_20200330111409229_20357
    Canonical exit: 21 Mar 2019 (T+90)
  • ▲
    PDMRExecutives4D Pharma plc
    22,800 GBP14FCA-NSM
    20,000 shares@ £1.1428.2% of flowLondon Stock Exchange, AIMISIN GB00BJL5BR07FCA-NSM:LSE20181219070004_13908850_20200330111409092_17501
    Canonical exit: 19 Mar 2019 (T+90)

6 of 6 declarations